IMRT using simultaneous integrated boost (66 Gy in 6 weeks) with and without concurrent chemotherapy in head and neck cancer - Toxicity evaluation

Reports of Practical Oncology and Radiotherapy

Volumn 13, Issue 2, 2008, Pages 86-95

  Vošmik, Milan ^a   Kordač, Petr ^a   Paluska, Petr ^a   Zouhar, Milan ^a   Petera, Jiří ^a   Odrážka, Karel ^a   Veselý, Pavel ^a   Dvořák, Josef ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Head and neck cancer; Intensity modulated radiotherapy; Toxicity

Indexed keywords

CISPLATIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESQUAMATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS DISEASE; FEMALE; FISHER EXACT TEST; FOLLOW UP; GRAFT REJECTION; HEAD AND NECK CANCER; HERPES VIRUS INFECTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY TRANSPLANTATION; LARYNX DISORDER; LARYNX EDEMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARYNX DISEASE; POSTOPERATIVE PERIOD; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RATING SCALE; SALIVARY GLAND DISEASE; SIDE EFFECT; SKIN DISEASE; SPEECH DISORDER; SPINAL CORD DISEASE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TRISMUS; TUMOR LOCALIZATION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 51349105382     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1507-1367(10)60087-9     Document Type: Article

References (25)

1. Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2000; 48: 711-22.
2. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22.
3. Huang D, Xia P, Akazawa P, et al. Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003; 56: 158-68.
4. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 45: 577-87.
5. Roesink JM, Moerland MA, Battermann JJ, Hordijk GJ, Terhaard CH. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2001; 51: 938-46.
6. Braam PM, Terhaard CH, Roesink JM, Raaijmakers CP. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66: 975-80.
7. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006; 66: 981-91.
8. Dogan N, King S, Emami B, et al. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003; 57: 1480-91.
9. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000; 46: 619-30.
10. Wu Q, Manning M, Schmidt-Ullrich R, Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000; 46: 195-205.
11. Niemierko A. A generalized concept of equivalent uniform dose (abstract). Med Phys 1999; 26: 1100.
12. Eisbruch A, Harris J, Garden A, et al. Phase II Multi-institutional study of IMRT for oropharyngeal cancer (RTOG 00-22): Early results. Int J Radiat Oncol Biol Phys 2006; 66 (Suppl. 1): S46-7.
13. Lauve A, Morris M, Schmidt-Ullrich R, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II-clinical results. Int J Radiat Oncol Biol Phys 2004; 60: 374-87.
14. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003; 57: 49-60.
15. Yao M, Dornfeld KJ, Buatti JM, et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma-the University of Iowa experience. Int J Radiat Oncol Biol Phys 2005; 63: 410-21.
16. Butler EB, Teh BS, Grant WH 3rd, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 45: 21-32.
17. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004; 60: 1440-50.
18. Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 966-74.
19. Sanguineti G, Pou AM, Newlands SD. Accelerated Hyperfractionated Intensity Modulated Radiotherapy (AHI) for T2-3 Oropharyngeal Carcinoma: Preliminary Results from a Phase I-II Study. Int J Radiat Oncol Biol Phys 2005; 63 (Suppl.1): S380.
20. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000; 47: 1-12.
21. Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 2003; 69: 161-8.
22. Maguire PD, Meyerson MB, Neal CR, et al. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 2004; 58: 698-704.
23. Cheng SH, Jian JJ, Tsai SY, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2000; 48: 1323-30.
24. Lee SW, Back GM, Yi BY, et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65: 152-60.
25. Nakamura K, Shioyama Y, Sasaki T, et al. Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int J Radiat Oncol Biol Phys. 2005; 62: 680-3.